ArticleRespiratory research2026
Krüppel-like factor 14 enhances fatty acid oxidation to combat pulmonary fibrosis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive lung disorder with few effective treatments. This study examines how Krüppel-like factor 14 (KLF14) influences fatty acid oxidation (FAO) and fibroblast senescence in IPF.
methodsA rat model of IPF was induced using bleomycin. Expression levels of KLF14, CPT1A, and related proteins were measured using qRT-PCR and Western blot. Lung tissue histology was examined, and cellular senescence was evaluated using SA-β-gal staining. The transcriptional regulation of CPT1A by KLF14 was confirmed through luciferase reporter assays and ChIP.
resultsKLF14 expression was significantly downregulated in the IPF model. Overexpression of KLF14 reduced collagen deposition, attenuated fibroblast senescence, and enhanced FAO by upregulating CPT1A. Mechanistically, KLF14 binds to the CPT1A promoter, promoting its transcription.
conclusionsKLF14 enhances FAO through CPT1A activation, offering a novel therapeutic strategy for IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.